£5.9m market cap

7.5p last close

NetScientific is a transatlantic biomedical and healthcare technology group. Its portfolio of five core investments and one material investment is focused on three main sectors: digital heath (Wanda), diagnostics (Vortex, ProAxsis, Glycotest) and therapeutics (PDS Biotech).

Investment summary

NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. Following a review of strategic alternatives, NetScientific has decided to de-list from the AIM and be a private company going forward. They also sold off their interests in core portfolio holdings Wanda and Vortex.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2016A 0.5 (12.6) (12.3) (20.6) N/A N/A
2017A 0.4 (10.8) (9.5) (13.6) N/A N/A
2018E N/A N/A N/A N/A N/A N/A
2019E N/A N/A N/A N/A N/A N/A
Industry outlook

NetScientific remains focused on sourcing, funding and building early- to mid-stage US and UK companies that are developing potentially breakthrough technologies in growing markets with unmet needs.

Last updated on 25/07/2019
Share price graph
Balance sheet
Forecast net debt (£m) 0.3
Forecast gearing ratio (%) 4
Price performance
Actual (14.3) (25.0) (78.6)
Relative* (15.4) (25.1) (77.9)
52-week high/low 36.0p/1.8p
*% relative to local index
Key management
Sir Richard Sykes Chairman
Dr François Martelet CEO
Ian Postlethwaite CFO

Content on NetScientific